Related Experiment Videos
ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide
K Kalman1, M W Pennington, M D Lanigan
1Departments of Physiology & Biophysics, and Microbiology and Molecular Genetics, University of California, Irvine, California 92697-4560, USA.
The Journal of Biological Chemistry
|November 26, 1998
Summary
A novel ShK peptide, ShK-Dap22, selectively blocks T-lymphocyte Kv1.3 channels. This potent immunosuppressant shows low toxicity, offering potential for treating autoimmune diseases and preventing graft rejection.
Area of Science:
- Immunology
- Molecular Pharmacology
- Biochemistry
Background:
- Kv1.3 channels are key targets for immunosuppression in T lymphocytes.
- The sea anemone peptide ShK is a potent inhibitor of Kv1.3 and related potassium channels.
Purpose of the Study:
- To determine the binding configuration of ShK to Kv1.3.
- To engineer a more selective and potent Kv1.3 inhibitor.
- To evaluate the therapeutic potential of the engineered peptide.
Main Methods:
- Mutant cycle analysis and complementary mutagenesis of ShK and Kv1.3.
- Structural analysis using Nuclear Magnetic Resonance (NMR).
- In vitro T-lymphocyte proliferation assays and in vivo toxicity studies.
Main Results:
- A likely docking model for ShK in Kv1.3 was established.
- ShK-Dap22, a modified ShK peptide, demonstrated high selectivity and potency against Kv1.3.
- ShK-Dap22 suppressed T-lymphocyte activation in vitro and exhibited low toxicity in vivo.
Conclusions:
- ShK-Dap22 is a potent and selective Kv1.3 channel blocker.
- The modified peptide shows promise as an immunosuppressant for autoimmune diseases and transplant rejection.
- Further development of ShK-Dap22 or analogues is warranted for clinical applications.